60 Degrees Pharmaceuticals CEO Geoffrey Dow Buys Shares
Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, acquired 7,350 shares on June 12, 2026.
Key Points
- Geoffrey Dow, President and CEO of 60 Degrees Pharmaceuticals, purchased 7,350 shares of the company's stock at an average price of $1.38 each on June 12, 2026.
- 60 Degrees Pharmaceuticals, trading under NasdaqCM: SXTP, has a market cap of approximately $3.96 million with shares recently trading at $1.49.
- Analysts from Ascendiant Capital and HC Wainwright & Co. maintain buy ratings with price targets ranging from $3.7 to $24.0.
Geoffrey Dow, the President and CEO of 60 Degrees Pharmaceuticals, Inc., recently bought 7,350 shares of the company on June 12, 2026. The shares were purchased at an average price of $1.38 each, totaling $10,143. This insider transaction was not part of a pre-planned trading program.
Insider Buying and Selling at 60 Degrees Pharmaceuticals, Inc.
Geoffrey Dow has been actively buying shares of 60 Degrees Pharmaceuticals. Alongside his recent purchase, previous transactions include buying 9,670 shares at $0.8024 each on December 15, 2025, and acquiring 3,613 shares at $0.9184 each on December 11, 2025.
Other Institutional Activity in 60 Degrees Pharmaceuticals
Institutional investors have been adjusting their holdings in 60 Degrees Pharmaceuticals. Kathmere Capital Management, LLC increased its stake by 144,683 shares, bringing its total to 144,683 shares valued at approximately $253,195. UBS Group AG acquired 31,410 shares, now holding shares worth about $54,968. Geode Capital Management, LLC added 16,295 shares, reaching a total of 16,295 shares valued at $28,516. Barclays PLC and NewEdge Advisors, LLC also increased their holdings, with shares totaling 1,856 and 50, respectively.
60 Degrees Pharmaceuticals Stock Snapshot
Shares of 60 Degrees Pharmaceuticals, traded under NasdaqCM: SXTP, were recently priced at $1.49. The company has a market capitalization of approximately $3.96 million. The stock has experienced a 52-week low of $1.22 and a high of $10.77. Its 50-day moving average is $1.59, while the 200-day moving average is $3.41. The company has a high beta of 2.652, indicating significant volatility compared to the market.
Recent Earnings
60 Degrees Pharmaceuticals reported revenue of $1.31 million, though it experienced a revenue decline of 36.8%. The company is not currently profitable, with a negative return on equity of -172.8%. The next earnings report is expected on August 12, 2025.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on 60 Degrees Pharmaceuticals. On May 22, 2026, Ascendiant Capital reaffirmed its buy rating with a price target of $3.7. HC Wainwright & Co. also maintained a buy rating, setting a high target of $24.0 on January 27, 2026. The consensus target price is $3.7, based on one analyst's opinion.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Washington, D.C. It focuses on developing and commercializing therapies for infectious diseases. The company offers Arakoda for malaria prevention and is working on therapies for COVID-19, babesiosis, and other diseases. Founded in 2010, it is led by CEO Dr. Geoffrey Stuart Dow.
Bottom Line
Geoffrey Dow's recent stock purchase reflects his confidence in 60 Degrees Pharmaceuticals. Investors often watch insider transactions for potential insights into company prospects. However, it's important to remember that insider trades are just one piece of the puzzle. The company's stock remains volatile, and its financial performance is under pressure, as indicated by recent earnings data.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.